Biochem/physiol Actions
FT895 is a potent and highly selective HDAC11 inhibitor (IC50 = 3 nM/HDAC11, 5.6 μM/HDAC8, >10 μM/HDAC1-7, HDAC9 & HDAC10) with a deacetylase active site Zn2+-targeting hydroxamate. FT895 exhibits antiproliferation potency against myeloproliferative neoplasm (MPN) cultures (IC50 = 3.00 μM/JAK2(V617F) Ba/F3, 4.94 μM/HEL92.1.7, 6.49 μM/MPL(W515L) Ba/F3) and reduces stem-like properties of CSCs (42/62/85/100% inhibtion of H1650 Sphere formation at 0.5/1/2/5 μM).
Potent and highly selective HDAC11 inhibitor that reduces myeloproliferative neoplasm (MPN) proliferation and CSCs stem-like properties.